8-K: BIOLASE, Inc. Faces Delisting from Nasdaq, to Transition to OTC Markets

BIOLASE, Inc. has been notified by Nasdaq that its common stock will be delisted and trading will be suspended on June 20, 2024, due to non-compliance with listing rules.

Summary

• BIOLASE, Inc. received notice from Nasdaq on June 17, 2024, that its common stock will be delisted.
• The delisting is due to the company's failure to meet the minimum bid price requirement of $1.00 and the minimum stockholders' equity requirement of $2.5 million.
• Trading of BIOLASE's stock on Nasdaq will be suspended at the open of trading on June 20, 2024.
• The company's stock is expected to begin trading on the OTC Markets system under the symbol BIOL on June 20, 2024.
• BIOLASE has 15 days, until July 2, 2024, to request a review of the delisting decision by the Nasdaq Listing and Hearing Review Council.
• The Council may also review the decision on its own within 45 days of the company being notified.
• BIOLASE has applied to the OTCQB for quotation of its common stock and will continue to file required reports with the SEC.

Sentiment

Score: 3

Explanation: The document indicates a significant negative event for the company, with delisting from Nasdaq and a transition to the OTC markets. This is likely to negatively impact investor confidence.

Positives

• BIOLASE has submitted an application to the OTCQB for quotation of its common stock, indicating a plan to continue trading.
• The company plans to continue filing required periodic reports and other filings with the SEC, maintaining transparency.

Negatives

• BIOLASE has failed to meet Nasdaq's minimum bid price and equity requirements.
• The company's stock will be delisted from Nasdaq, a major exchange.
• Trading of the company's stock will be suspended on Nasdaq starting June 20, 2024.

Risks

• The delisting from Nasdaq could negatively impact investor confidence and the company's stock price.
• Trading on the OTC Markets may result in lower liquidity and potentially higher volatility.
• There is a risk that the Nasdaq Listing and Hearing Review Council may not overturn the delisting decision.
• The company's ability to raise capital may be affected by the delisting.

Future Outlook

The company plans to continue trading on the OTC Markets and will continue to file required reports with the SEC. They have also applied to the OTCQB for quotation of its common stock.

Management Comments

• The company's senior management and outside advisors outlined the company's compliance plan to the Nasdaq Hearings Panel on June 4, 2024.

Industry Context

This delisting highlights the challenges faced by companies struggling to maintain compliance with exchange listing requirements, particularly in volatile market conditions. It is not uncommon for companies to transition to the OTC markets after failing to meet Nasdaq's listing standards.

Comparison to Industry Standards

• Many small-cap and micro-cap companies face challenges in maintaining Nasdaq listing requirements, particularly the minimum bid price and equity standards.
• Companies like BIOLASE that fail to meet these standards often transition to the OTC markets, which have less stringent requirements.
• Other companies that have faced similar delisting issues include those in the biotech and technology sectors, which can be subject to high volatility and fluctuating valuations.
• The transition to the OTC markets is a common path for companies that are unable to maintain the listing requirements of major exchanges.

Stakeholder Impact

• Shareholders will likely experience a negative impact due to the delisting and potential decrease in stock value.
• Employees may be concerned about the company's future prospects.
• Customers and suppliers may experience uncertainty regarding the company's stability.

Next Steps

• BIOLASE will begin trading on the OTC Markets on June 20, 2024.
• The company has until July 2, 2024, to request a review of the delisting decision.
• BIOLASE will continue to file required reports with the SEC.

Key Dates

Keywords

delisting, Nasdaq, BIOLASE, OTC Markets, stock, compliance, bid price, equity, trading suspension, OTCQB